Anti-Human CXCL13 (BCA-1) (Clone CPTC-CXCL13-1) – Purified No Carrier Protein

CXCL13 synthetic peptide SIVC[cam]VDPQAEWIQR

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0142B-6G9-H1/K2 activity is directed against human CXCL13 peptide sequence SIVCVDPQAEWIQR.

CPTC-CXCL13-1

Chemotactic cytokines, along with their GPCR receptors, play important roles in regulating lymphoid tissue development, immune homeostasis, and inflammatory responses by directing leukocyte migration into injured or infected tissues¹. Additionally, chemokine signaling in the tumor microenvironment contributes to tumor cell proliferation, migration, invasion, angiogenesis, evasion, and resistance to immune checkpoint inhibitors.

CXCL13, with its receptor CXCR5, strongly attracts B lymphocytes and promotes the migration of a small number of T cells and macrophages¹. CXCL13/CXCR5 are essential for the development of B cell zones of secondary lymphoid organs (i.e., spleen lymph nodes, Peyer’s patches) and are involved in the development of tertiary lymphoid structures that activate immune responses against some tumors. CXCL13/CXCR5 signaling also enhances B cell receptor (BCR)-triggered B cell activation. Additionally, CXCL13 can be induced by environmental carcinogens and can promote cancer by recruiting suppressive immune cells into tumor tissues and is also involved in some autoimmune diseases via inflammatory pathways. CXCL13 is a target for cancer immunotherapy.

EB0142B-6G9-H1/K2 was generated in rabbit using a synthetic peptide derived from human CXCL13 that is carbamidomethylated at the cysteine, SIVC[cam]VDPQAEWIQR². EB0142B- 6G9-H1/K2 does not detect CXCL13 by immunohistochemistry, reverse phase protein array, or Western blotting³.

CXCL13 is expressed on follicular helper T cells, follicular dendritic cells, and stromal cells in the follicles of secondary lymphoid organs. Additionally, CXCL13 is expressed by CD4 T cells in tertiary lymphoid structures and CD8 T cells in tumor infiltrating lymphocytes.

BLR1/CXCR5

1 Gao SH, Liu SZ, Wang GZ, et al. Life (Basel). 11(12):1282. 2021.
2 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
3 https://antibodies.cancer.gov/detail/CPTC-CXCL13-1#CPTC-CXCL13-1